Document is current
Any future updates will be listed below
-
Authors
Suzuki, Takanori
Matsuura, Kentaro
Tahata, Yuki
Hikita, Hayato
Sakamori, Ryotaro
Kawada, Norifumi
Enomoto, Nobuyuki
Miki, Daiki
Yatsuhashi, Hiroshi
Kuroda, Hidekatsu
Yamashita, Taro
Yoshiji, Hitoshi
Kurosaki, Masayuki
Mawatari, Seiichi
Miyaaki, Hisamitsu
Asahina, Yasuhiro
Hiasa, Yoichi
Mochida, Satoshi
Nakamoto, Yasunari
Takami, Taro
Kodama, Takahiro
Tatsumi, Tomohide
Takehara, Tetsuo
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP24fk0210113)
Gilead Sciences
- License Information
-
More Information
Article History
Received: 21 February 2025
Accepted: 23 June 2025
First Online: 1 July 2025
Declarations
:
: Satoshi Mochida received research grants from Janssen Pharmaceutical K. K., EA Pharma Co, Ltd., MIC Medical Corp., AbbVie GK, EPS International Holdings Co., Ltd. and Gilead Sciences, Inc. and scholarship grants from Toray Industries Inc, AbbVie GK, ASKA Pharmaceutical Co., Ltd, Eisai Co., Ltd, Sumitomo Dainippon Pharma Co., Ltd and EA Pharma Co., Ltd. and is on the speakers’ bureau for MSD K. K, Gilead Sciences, Inc, Toray Industries Inc, AbbVie GK, Sumitomo Dainippon Pharma Co., Ltd, Eisai Co., Ltd, Otsuka Pharmaceutical Co., Ltd and ASKA Pharmaceutical., Ltd. Norifumi Kawada received research grants from Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Co., Ltd, AstraZeneca plc, MSD co., Ltd, Gilead Sciences, Inc, GlaxoSmithKline plc and Bristol Myers Squibb. and scholarship grants from AbbVie GK, Otsuka Pharmaceutical Co., Ltd and Eisai Co., Ltd. and is on the speakers’ bureau for AbbVie GK, MSD Co., Ltd and Gilead Sciences, Inc. Masayuki Kurosaki is on the speakers’ bureau for Gilead Sciences, Inc and AbbVie GK. Hitoshi Yoshiji received research grants from AbbVie GK, Otsuka Pharmaceutical Co., Ltd and Asuka Pharmaceutical Co., Ltd. and is on the speakers’ bureau for Gilead Sciences, Inc, Otsuka Pharmaceutical Co., Ltd, Sumitomo Dainippon Pharma Co., Ltd, Asuka Pharmaceutical Co., Ltd and AbbVie GK. Taro Takami is on the speakers’ bureau for Gilead Sciences, Inc., AbbVie GK, and Otsuka Pharmaceutical Co., Ltd. Yasuhiro Asahina belongs to a donation-funded department funded by Gilead Sciences, Inc., AbbVie GK, Toray Industries Inc and Fujirebio Inc. Tetsuo Takehara received research grants from Gilead Sciences, Inc., MSD, AbbVie GK. and Chugai Pharmaceutical Co., Ltd. and is on the speakers’ bureau for Gilead Sciences, Inc., AbbVie GK and MSD. Takahiro Kodama is on the speakers’ bureau for Gilead Sciences, Inc., and AbbVie GK. All other authors declare that they have no conflicts of interest to disclose.
: This study was approved by the institutional review board at Osaka University Hospitals (18431 and 22285) and all other institutions.
: Basically, informed consent was obtained from study patients. Registry and the Registration No. of the study/trial: This study was registered to the University Hospital Medical Information Network (36150).
: N/A.
